肾移植患者中地舒单抗与双膦酸盐的临床有效性和安全性比较
该回顾性病历回顾纳入85例19-88岁肾移植患者,比较地舒单抗与双膦酸盐对骨密度及不良事件的影响。两组均增加腰椎骨密度,但地舒单抗增幅更大,且地舒单抗组股骨颈骨密度增加而双膦酸盐组下降。地舒单抗组报告1例严重低钙血症和1例肺炎住院,双膦酸盐组无严重不良事件。
要点
- 地舒单抗增加腰椎和股骨颈骨密度均优于双膦酸盐。
- 双膦酸盐组股骨颈骨密度在末次随访时平均下降。
- 地舒单抗组需警惕低钙血症,报告1例严重事件。
核心结论
- 地舒单抗和双膦酸盐均增加肾移植患者腰椎骨密度,但地舒单抗效果更强。
- 地舒单抗增加股骨颈骨密度,而双膦酸盐组股骨颈骨密度平均下降。
- 地舒单抗治疗肾移植患者有效,但需 caution 低钙血症。
研究设计与样本
- 回顾性病历回顾,纳入85例19-88岁接受地舒单抗或双膦酸盐治疗的肾移植患者。
- 比较基线、第1、2、3年及末次随访(平均3.4年)的骨密度测定。
主要发现
- 双膦酸盐组腰椎和股骨颈骨密度绝对变化分别为0.029 ± 0.075 g/cm2和-0.003 ± 0.064 g/cm2。
- 地舒单抗组末次随访腰椎和股骨颈骨密度绝对变化分别为0.072 ± 0.094 g/cm2和0.025 ± 0.063 g/cm2。
- 地舒单抗组腰椎骨密度增加比双膦酸盐组多0.045 g/cm2。
- 地舒单抗组股骨颈骨密度绝对变化比双膦酸盐组多0.022 g/cm2。
- 地舒单抗组报告1例首次注射后严重低钙血症和1例肺炎住院,双膦酸盐组无严重不良事件。
关键数值与推荐
- 双膦酸盐组腰椎骨密度绝对变化0.029 ± 0.075 g/cm2,股骨颈-0.003 ± 0.064 g/cm2。
- 地舒单抗组腰椎骨密度绝对变化0.072 ± 0.094 g/cm2,股骨颈0.025 ± 0.063 g/cm2。
- 地舒单抗组腰椎骨密度增加比双膦酸盐组多0.045 g/cm2,股骨颈多0.022 g/cm2。
临床怎么用
- 肾移植患者可考虑地舒单抗以更有效增加腰椎和股骨颈骨密度。
- 使用地舒单抗时需监测低钙血症,尤其首次注射后。
局限性
- 回顾性病历回顾设计,样本量85例。
- 作者建议需更多前瞻性研究分析长期抗骨吸收治疗的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: A retrospective chart review was conducted on 85 renal transplant patients aged 19-88 years, treated with denosumab or bisphosphonate therapy. Bone densitometry measures were compared between treatment groups at baseline; at years 1, 2, and 3; and at final follow-up (average of 3.4 years). Both bisphosphonate and denosumab treatments increased lumbar spine bone density; however, the effect of denosumab was greater compared with that of bisphosphonate treatment. Denosumab treatment increased femoral neck BMD, whereas bisphosphonate treatment had a mean decrease in femoral neck BMD at final follow-up. Thus, our study provides evidence for the efficacy of denosumab treatment in renal transplant patients. Caution around hypocalcemia is warranted. We recommend more prospective studies to analyze the effects of long-term antiresorptive therapy in patients with a renal transplant. INTRODUCTION: To compare the clinical effectiveness and safety between the use of denosumab and bisphosphonates on bone density and incidence of adverse events in renal transplant patients. METHODS: A retrospective chart review was conducted on 85 renal transplant patients aged 19-88 years, treated with denosumab or bisphosphonate therapy. Bone densitometry measures were compared between treatment groups at baseline; years 1, 2, and 3; and at final follow-up (average of 3.4 years). RESULTS: Absolute change in lumbar spine and femoral neck BMD over the treatment period was 0.029 ± 0.075 g/cm2 and - 0.003 ± 0.064 g/cm2, respectively, in the bisphosphonate group. Absolute change in lumbar spine and femoral neck BMD at final follow-up was 0.072 ± 0.094 g/cm2 and 0.025 ± 0.063 g/cm2, respectively, in the denosumab group. Denosumab resulted in significantly greater increases in lumbar spine BMD (0.045 g/cm2 greater in the denosumab group). Similarly, the absolute change in BMD at the femoral neck was 0.022 g/cm2 greater in the denosumab group as compared with the bisphosphonate group. The denosumab group had one event of severe hypocalcemia following first injection and one report of hospitalized pneumonia. No serious adverse events were reported in the bisphosphonate group. CONCLUSIONS: Both treatments increased lumbar spine BMD; however, the effect of denosumab was greater compared with that of bisphosphonate treatment. Our study provides evidence for the efficacy of denosumab treatment in renal transplant patients. Caution around hypocalcemia is warranted. We recommend more prospective studies to analyze the effects of long-term antiresorptive therapy in patients with a renal transplant.
引用
- McKee H, Ioannidis G, Lau A, et al. Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients. Osteoporos Int. 2020. PMID: 31900542. doi:10.1007/s00198-019-05267-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。